Quotidian nocturnal hemodialysis improves cytokine profile and enhances erythropoietin responsiveness

ASAIO Journal

Volumn 51, Issue 3, 2005, Pages 236-241

  Yuen, Darren ^a   Richardson, Robert M A ^a   Fenton, Stanley S A ^a   McGrath Chong, Margaret E ^a   Chan, Christopher T ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD; DISEASES; GROWTH KINETICS; HEMODYNAMICS; INSULIN; MEDICAL PROBLEMS; PATHOLOGY; PATIENT TREATMENT; PROTEINS; TUMORS;

ERYTHROPOIESIS; ERYTHROPROTEIN (EPO); RENAL DISEASES; TUMOR NECROSIS FACTOR (TNF);

DIALYSIS;

C REACTIVE PROTEIN; ERYTHROPOIETIN; HEMOGLOBIN; INTERLEUKIN 6; IRON; PARATHYROID HORMONE; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ASSOCIATION; ERYTHROCYTE; ERYTHROPOIESIS; FEMALE; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HUMAN; INFLAMMATION; IRON BLOOD LEVEL; KIDNEY FAILURE; MALE; NIGHT; NOCTURAL HEMODIALYSIS; UREMIA;

ADULT; ANEMIA; CYTOKINES; DRUG RESISTANCE; ERYTHROPOIETIN; FEMALE; HEMOGLOBINS; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; TIME FACTORS;

EID: 18744363652     PISSN: 10582916     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.MAT.0000160578.43422.60     Document Type: Article

References (43)

1. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am JKidney Dis 28: 53-61, 1996.
2. Ma JZ, Ebben J, Xia H, Collins AJ: Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 10: 610-619, 1999.
3. Canadian Erythropoietin Study Group: Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ 300: 573-578, 1990.
4. Cannella G, La Canna G, Sandrini M, et al: Reversal of left ventricular hypertrophy following recombinant human erythropoietin treatment of anaemic dialysed uraemic patients. Nephrol Dial Transplant 6: 31-37, 1991.
5. Locatelli F, Conte F, Marcelli D: The impact of haematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity - The experience of the Lombardy Dialysis Registry. Nephrol Dial Transplant 13: 1642-1644, 1998.
6. Macdougall IC, Cooper A: The inflammatory response and epoetin sensitivity. Nephrol Dial Transplant 17 (Suppl. 1): 48-52, 2002.
7. Lacombe C: Resistance to erythropoietin. N Engl J Med 334: 660-662, 1996.
8. Macdougall IC: Role of uremic toxins in exacerbating anemia in renal failure. Kidney Int Suppl 78 (Suppl.): 67-72, 2001.
9. Sitter T, Bergner A, Schiffl H: Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients. Nephrol Dial Transplant 15: 1207-1211, 2000.
10. Goicoechea M, Martin J, de Sequera P, et al: Role of cytokines in the response to erythropoietin in hemodialysis patients. Kidney Int 54: 1337-1343, 1998.
11. Brox AG, Zhang F, Guyda H, Gagnon RF: Subtherapeutic erythropoietin and insulin-like growth factor-1 correct the anemia of chronic renal failure in the mouse. Kidney Int 50: 937-943, 1996.
12. Correa PN, Axelrad AA: Production of erythropoietic bursts by progenitor cells from adult human peripheral blood in an improved serum-free medium: Role of insulinlike growth factor 1. Blood 78: 2823-2833, 1991.
13. Bergstrom J, Lindholm B, Lacson E, Jr., et al: What are the causes and consequences of the chronic inflammatory state in chronic dialysis patients? Semin Dial 13: 163-175, 2000.
14. Haubitz M, Brunkhorst R, Wrenger E, Froese P, Schulze M, Koch KM: Chronic induction of C-reactive protein by hemodialysis, but not by peritoneal dialysis therapy. Perit Dial Int 16: 158-162, 1996.
15. Haubitz M, Schulze M, Koch KM: Increase of C-reactive protein serum values following haemodialysis. Nephrol Dial Transplant 5: 500-503, 1990.
16. Ifudu O, Feldman J, Friedman EA: The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. N Engl J Med 334: 420-425, 1996.
17. Movilli E, Cancarini GC, Zani R, Camerini C, Sandrini M, Maiorca R: Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients. Nephrol Dial Transplant 16: 111-114, 2001.
18. Pierratos A: New approaches to hemodialysis. Annu Rev Med 55:179-189, 2004.
19. Schwartz DI, Pierratos A, Richardson RMA, Fenton SSA, Chan CT: Impact of nocturnal home hemodialysis on anemia management in patients with end-stage renal disease. Clin Nephro 63:202-208, 2005.
20. Ly J, Marticorena R, Donnelly S: Red blood cell survival in chronic renal failure. Am J Kidney Dis 44: 715-719, 2004.
21. IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000. Am J Kidney Dis 37 (Suppl.): 182-238, 2001.
22. Daugirdas JT, Greene T, Depner TA, Gotch FA, Star RA: Relationship between apparent (single-pool) and true (double-pool) urea distribution volume. Kidney Int 56: 1928-1933, 1999.
23. Jindal KK, Manuel A, Goldstein MB: Percent reduction in blood urea concentration during hemodialysis (PRU). A simple and accurate method to estimate Kt/V urea. ASAIO Transactions 33: 286-288, 1987.
24. Stenvinkel P, Pecoits-Filho R, Lindholm B: Coronary artery disease in end-stage renal disease: No longer a simple plumbing problem. J Am Soc Nephrol 14: 1927-1939, 2003.
25. Foley RN: Clinical epidemiology of cardiac disease in dialysis patients: Left ventricular hypertrophy, ischemic heart disease, and cardiac failure. Semin Dial 16: 111-117, 2003.
26. Stenvinkel P: Anaemia and inflammation: What are the implications for the nephrologist? Nephrol Dial Transplant 18 (Suppl. 8): 17-22, 2003.
27. Stenvinkel P, Barany P: Anaemia, rHuEPO resistance, and cardiovascular disease in end-stage renal failure; links to inflammation and oxidative stress. Nephrol Dial Transplant 17 (Suppl. 5): 32-37, 2002.
28. Owen WF, Jr., Lew NL, Liu Y, Lowrie EG, Lazarus JM: The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 329: 1001-1006, 1993.
29. Cavaillon JM, Poignet JL, Fitting C, Delons S: Serum interleukin-6 in long-term hemodialyzed patients. Nephron 60: 307-313, 1992.
30. Trey JE, Kushner I: The acute phase response and the hematopoietic system: The role of cytokines. Crit Rev Oncol Hematol 21:1-18, 1995.
31. Gaufriez A, Abramowicz D, Vanherweghem JL, Copinschi G: Insulin-like growth factor I values in patients on maintenance hemodialysis: Relationship to growth hormone and albumin levels. J Endocrinol Invest 16: 691-696, 1993.
32. Fouque D: Insulin-like growth factor 1 resistance in chronic renal failure. Miner Electrolyte Metab 22: 133-137, 1996.
33. Schouten WE, Grooteman MP, van Houte AJ, Schoorl M, van Limbeek J, Nube MJ: Effects of dialyser and dialysate on the acute phase reaction in clinical bicarbonate dialysis. Nephrol Dial Transplant 15: 379-384, 2000.
34. Pierratos A: Effect of therapy time and frequency on effective solute removal. Semin Dial 14: 284-288, 2001.
35. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH: Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101: 1767-1772, 2000.
36. Kalousova M, Sulkova S, Fialova L, et al: Glycoxidation and inflammation in chronic haemodialysis patients. Nephrol Dial Transplant 18: 2577-2581, 2003.
37. Papanastasiou P, Grass L, Rodela H, Patrikarea A, Oreopoulos D, Diamandis EP: Immunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis or CAPD. Kidney Int 46: 216-222, 1994.
38. Cacho CP, Erhard P, Priester A, Newman LN, Weiss MF: Nocturnal dialysis reduces serum pentosidine in patients with ESRD [Abstract]. Perit Dia Int 21 (Suppl.): 61, 2001.
39. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C: Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 55: 648-658, 1999.
40. Stenvinkel P, Barany P, Heimburger O, Pecoits-Filho R, Lindholm B: Mortality, malnutrition, and atherosclerosis in ESRD: What is the role of interleukin-6? Kidney Int 80 (Suppl.): 103-108, 2002.
41. Chan CT: Cardiovascular effects of frequent intensive hemodialysis. Semin Dial 17: 99-103, 2004.
42. McFarlane PA, Bayoumi AM, Pierratos A, Redelmeier DA: The quality of life and cost utility of home nocturnal and conventional in-center hemodialysis. Kidney Int 64: 1004-1011, 2003.
43. Chan CT: Nocturnal hemodialysis: An attempt to correct the "unphysiology" of conventional intermittent renal replacement therapy. Clin Invest Med 25: 233-235, 2002.